Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug empagliflozin studied for kidney disease mineral effects

NCT ID NCT06435858

Knowledge-focused Sponsor: Cantonal Hospital Graubuenden Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether the diabetes drug empagliflozin changes how the kidneys handle calcium, phosphate, and magnesium in people with autosomal dominant polycystic kidney disease (ADPKD). Forty adults will take either empagliflozin or a placebo for two weeks, then switch after a two-week break. The goal is to better understand electrolyte balance, not to treat the disease itself.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Empagliflozin
What this could lead to
If successful, this could help doctors understand how SGLT2 inhibitors affect electrolyte balance in ADPKD, potentially guiding future treatment strategies.
What could go wrong
This is a small, early-phase study (40 people) looking only at short-term effects over 2 weeks. It is not designed to test long-term benefits or risks, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Oct 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Patients 18-75 years old with ADPKD, defined according to international diagnostic and classification criteria14, treated at Cantonal Hospital Graubünden (KSGR) and the University Hospital Zürich (USZ) independent of baseline treatment with the vasopressin receptor antagonist Tolvaptan * Informed consent as documented by signature Exclusion Criteria: * \- renal replacement therapy or kidney allograft recipient * chronic kidney disease CKD KDIGO Stage G4 (eGFR under 30ml/min/1.73m2) * patients younger 18 years of age * Diabetes mellitus type 1 * recurrent urinary tract infections (UTI) defined as more than 3 infections requiring antibiotic treatment or over 1 requiring hospitalization/year. * Patients with uncontrolled hypertension (defined as ambulatory systolic BP over 180mmHg), liver cirrhosis (Child Pugh B and C) * Patients not able or not willing to stop the following medications during the study period of participation in the trial: * Thiazide diuretics * Carbonic anhydrase inhibitors * Sodium bicarbonate * 1, 25 (OH) vitamin D (calcitriol) * Bisphosphonate, denosumab, teriparatide * Pregnant or lactating women * Known allergy to study drug * Inability to understand and follow the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autosomal dominant polycystic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autosomal dominant polycystic kidney disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cantonal Hospital Graubuenden

    RECRUITING

    Chur, Kanton Graubünden, 7000, Switzerland

  • University Hospital Zurich, Division of Nephrology

    RECRUITING

    Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.